About City of Hope

City of Hope is an independent biomedical research and treatment organization for cancer, diabetes and other life-threatening diseases.

Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy, such as CAR T cell therapy. City of Hope's translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution.

A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation's "Best Hospitals" in cancer by U.S. News & World Report and received Magnet® recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with more than 35 clinical network locations throughout Southern California. AccessHope™, a subsidiary launched in 2019, serves employers and their health care partners by providing access to City of Hope's specialized NCI-designated cancer center expertise.

To refer a patient:

- Call **800-COH-4DRS (264-4377)**, Monday through Friday, 8 a.m. to 6 p.m., to speak with a patient referral specialist.
- Fax a referral request letter with a patient face sheet to **626-301-8432**.
- Complete an online referral request form at **CityofHope.org/refer-a-patient**.
- To refer a patient to one of our clinical trials, please call **626-218-1133** or visit **clinicaltrials.coh.org**.
- To refer a patient to one of our CAR T trials, please call **833-310-CART (2278)** or visit **CityofHope.org/CAR-T**.

City of Hope®

1500 E. Duarte Road
Duarte, CA 91010
(866) 905-HOPE

CityofHope.org

©2021 City of Hope and the City of Hope logo are registered trademarks of City of Hope. City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.

20000-NEW-43898

City of Hope®

CLINICAL LEADERSHIP

Department of Hematology & Hematopoietic Cell Transplantation

Providing patients with personalized treatment and care, and access to world-class research and innovation

City of Hope focuses on **breakthrough treatments for all hematologic cancers**. Our Department of Hematology & Hematopoietic Cell Transplantation is a global pioneer in stem cell transplantation, having performed over 17,000 bone marrow transplants (BMT) to date with exceptional survival rates, according to the Center for International Blood & Marrow Transplant Research. We perform more bone marrow transplants than any other hospital in the region and are among the top three hospitals in the nation in terms of total transplants performed.

- **Extending curative BMT therapy to more patients** — With regimens that capitalize on the graft-versus-tumor effect rather than on intense chemotherapy and radiation, this curative therapy is now available to patients over 70 years of age.
- **Breaking the age barrier for BMT candidacy** — Older patients with lymphoblastic leukemia, acute myeloid leukemia, myelodysplasia and myeloproliferative disorders are now evaluated for BMT like their young counterparts, with the expectation of long-term cure of their bone marrow disorder.
- **Advancing the haploidentical transplant program** in the treatment of blood cancers — 400 haploidentical transplants have been accomplished in the last five years, and successful half-matches in BMT have provided second chances for countless patients.
- **Pioneering strategy for the prevention of cytomegalovirus**
- **Pioneering CAR T cell therapy with on-site CAR T cell engineering and manufacturing** in good manufacturing practice facilities — Over 630 patients have been treated on multiple CAR T cell therapy trials targeting both solid tumors and hematologic malignancies.
- **Among the first to utilize** CAR T cell therapy as a bridge to transplant.
- **Exceeding both SEER LA and SEER national median survival for multiple myeloma** — Multiple myeloma survival at City of Hope is more than double the Los Angeles area survival at all ages, while its median survival is over 120% longer than the national survival (all ages).*

*Based on the National Cancer Institute's SEER (Surveillance, Epidemiology and End Results) Program November 2018 Disease Specific Files and City of Hope's cancer registry (CNeXT)



The Department of Hematology & Hematopoietic Cell Transplantation has a dedicated, multidisciplinary team that blends innovative research discoveries with superior clinical treatments. The result is improved outcomes for patients with various blood cancers, blood abnormalities and other hematologic disorders.

City of Hope focuses on breakthrough treatments for all hematologic cancers:

- Leukemia
  - Acute myeloid leukemia
  - Acute lymphoblastic leukemia
  - Chronic myelogenous leukemia
  - Chronic lymphocytic leukemia
- Lymphoma
  - Hodgkin's lymphoma
  - Non-Hodgkin's lymphoma
- Myeloma
- Myelodysplastic syndrome (blood abnormalities that can be life-threatening or lead to cancer)
- Other hematologic disorders

To find out more about City of Hope's Department of Hematology & Hematopoietic Cell Transplantation, visit **www.CityofHope.org/hct**.

Led by Eileen P. Smith, M.D., and F. Marc Stewart, M.D.

Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation; Professor and Chair, Department of Hematology & Hematopoietic Cell Transplantation

Professor and Vice Chair, Department of Hematology & Hematopoietic Cell Transplantation

GROUNDBREAKING RESEARCH

Hematologic Malignancies Research Institute

City of Hope's Hematologic Research Institute is one of the largest and most successful research and treatment centers in the world. We pioneer innovations in hematologic cancers, stem cell transplants and CAR T cell therapy into early stage clinical trials, ultimately translating them into breakthrough treatments.

The institute is a matrix of seven centers, each with a focus on a particular disease or treatment modality. Because specific diseases can frequently be treated by multiple modalities, there is deliberate collaboration between centers to optimize clinical outcomes.

Unlike other cancer centers, City of Hope has three on-site, certified good manufacturing practice facilities that allow us to go from discovery to clinical trials in an expeditious manner. A hybrid of research and development, our multidisciplinary team of scientists, clinical staff and manufacturing specialists work side by side to advance treatment possibilities to more patients.

Judy and Bernard Briskin Center for Multiple Myeloma Research

As one of the largest programs of its kind in California, Briskin Center sees over 300 new patients with this rare disease per year and leads the development of a large, diverse clinical trial portfolio of over 15 active phase trials for every phase of multiple myeloma. Researchers are aggressively pursuing new research and improved treatments for multiple myeloma and amyloidosis.

Led by Amrita Krishnan, M.D., and Jonathan Keats, Ph.D.

Professor and Chief, Division of Multiple Myeloma, Department of Hematology & Hematopoietic Cell Transplantation

Head, TGen Multiple Myeloma Research Laboratory

Center for Stem Cell Transplantation

The mission of this research team is to reduce treatment toxicity and improve patient outcomes using leading-edge research to advance hematopoietic stem cell transplant methods. The team has access to a large transplant patient population, rich historical data and a clinical department with a reputation for outstanding transplant outcomes.

Directed by Ryotaro Nakamura, M.D.

Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation



Center for Gene Therapy

A world-class leader in research on genetic modification of stem cells, the Center for Gene Therapy is dedicated to converting that research into real-world treatments and cures as rapidly as possible. Research includes using a patient's own blood stem cells to introduce new genes or small noncoding RNAs that will combat cancer, HIV/AIDS, hemophilia, sickle cell disease and other deadly diseases.

Led by John Zaia, M.D.

Aaron D. Miller and Edith Miller Chair for Gene Therapy

Gehr Family Center for Leukemia Research

The Gehr Family Center for Leukemia Research has a mission to further expand and broaden our world-renowned work in the research and treatment of all forms of leukemia, with a particular emphasis on acute myeloid leukemia, a major cause of death in older patients. Research includes new actionable molecular targets, developing novel targeted therapies and implementing these therapies in precision medicine approaches.

Led by Guido Marcucci, M.D., and Anthony S. Stein, M.D.

Professor and Chair, Department of Hematologic Malignancies Translational Science; Chief, Division of Leukemia

Professor, Department of Hematology and Hematopoietic Cell Transplantation

Toni Stephenson Lymphoma Center

The Toni Stephenson Lymphoma Center is an international leader in finding innovative treatments for lymphoma by developing immune-based, nontransplant therapies. The center has also earned its third Lymphoma Specialized Programs of Research Institute (SPORE) grant from the National Cancer Institute (NCI), one of just four current NCI-supported lymphoma SPORES in the nation and totaling $12.5 million. In addition, City of Hope holds one of the two mantle cell lymphoma Specialized Center of Research awards in the U.S.

Led by Larry Kwak, M.D. Ph.D., and Alexey Danilov, M.D., Ph.D.

Dr. Michael Friedman Professor in Translational Medicine; Deputy Director, Comprehensive Cancer Center

Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation



Cellular Immunotherapy Center

City of Hope is home to one of the most comprehensive CAR T cell therapy programs globally. With CAR T cell engineering and manufacturing in our good manufacturing practice facilities, we are one of only a handful of centers in the country applying proprietary CAR T technology in active preclinical and clinical programs across a range of hematologic cancers and solid tumors. Over 630 patients have received CAR T cell therapy to date — 40% of these were treated with City of Hope-developed constructs.

Led by Christine Brown, Ph.D., and Stephen J. Forman, M.D.

The Heritage Provider Network Professor in Immunotherapy

Director, Hematologic Malignancies Research Institute

Center for Survivorship and Outcomes

Care and consideration for our patients extends beyond treatment. The goal of the Center for Survivorship and Outcomes is to improve the overall quality of life for survivors of hematologic (blood, bone marrow, lymph node) cancers. City of Hope has one of the largest cohorts (>11,000) of long-term hematopoietic cell transplantation survivors in active follow-up. Each year, we celebrate our survivors and their families, who live across the United States and all over the world.

Led by Saro Armenian, D.O., M.P.H.

The Norman and Sadie Lee Foundation Professor in Pediatrics

Learn more about the Hematologic Malignancies Research Institute at **CityofHope.org/hem-institute**.